胰腺外分泌功能不全（PEI）具有病因复杂、发病率高、临床表现特异性差、并发症多、需长期治疗等特点。目前临床诊疗中存在漏诊率高、治疗规范化程度不足、缺乏个体化治疗指导原则、缺少多学科协作（MDT）治疗路径、合并症管理不到位等诸多问题。因此，明确PEI的病因及临床特点，在规范诊疗的基础上实施个性化药物治疗及药学监护，已成为解决临床诊疗困境的迫切需求。基于现有循证医学证据，结合国内多学科专家临床经验，制定《胰腺外分泌功能不全合理用药专家共识》，对PEI的治疗目标、药物治疗方案与随访管理要求进行系统阐述，针对不同病因所致PEI的重点人群提出针对性用药建议，同时制定MDT临床诊疗路径与药学服务路径，以期提升PEI药物治疗的规范化、合理化与个体化水平，最终助力改善患者临床结局。

Pancreatic exocrine insufficiency (PEI) is characterized by multifactorial etiology, high incidence, poor specificity of clinical manifestations, multiple complications, and the requirement for long-term clinical management. Nevertheless, current clinical practice encounters multiple challenges, including high missed diagnosis rate, low degree of treatment standardization, absence of individualized treatment guidelines, lack of multidisciplinary team (MDT) pathways, and insufficient management of comorbidities. Accordingly, elucidating the etiology and clinical characteristics of PEI, and implementing individualized pharmacotherapy and pharmaceutical care on the basis of standardized diagnosis and treatment, has become an urgent requirement to address the current dilemmas in clinical diagnosis and treatment. Based on available evidence-based medical evidence and incorporating the clinical expertise of Chinese multidisciplinary specialists, we have developed the “Expert Consensus on Rational Drug Use for Pancreatic Exocrine Insufficiency”, which systematically elaborates on the treatment objectives, pharmacotherapy regimens, and follow-up management requirements for PEI. This consensus puts forward targeted medication recommendations for key patient populations with PEI caused by different etiologies, and also establishes MDT clinical management pathways and pharmaceutical care pathways. These efforts are intended to improve the standardization, rationality and individualization of PEI pharmacotherapy, and ultimately help improve patients’ clinical outcomes.

R975

天津市医学重点学科建设项目（TJYXZDXK-3-007B）；国家卫生健康委能力建设和继续教育中心2025年度慢病管理研究课题（GWJJMB202510024013）